PanTher Founders Honored by National Pancreas Foundation
PanTher founders Laura Indolfi, David Ting and Elazer Edelman received the “Visions of Hope Award” from the Massachusetts Chapter of The National Pancreas Foundation at the chapter’s “Party for a Cure – Boston Gala.” The event, which raised over $230,000 to support the NPF in research and its mission to find cures for all pancreatic diseases, was held at The Harvard Club located in Back Bay, Boston.
Massachusetts Next Generation Initiative (MassNextGen) Program Winners Look Back
In June of 2018, the Massachusetts Life Sciences Center (MLSC) announced the winners of the first Massachusetts Next Generation Initiative (MassNextGen), a competitive program to support women entrepreneurs in early-stage life sciences companies. Laura Indolfi of PanTher Therapeutics and Elizabeth O’Day of Olaris Therapeutics were two of the five women-led companies in that first cohort.
Read More about Massachusetts Next Generation Initiative (MassNextGen) Program Winners Look Back
Drug Delivery Directly to the Tumor – Innovation Blog | Mass General Brigham
PanTher founder Dr. David Ting, MD was featured in the Mass General Brigham’s Innovation Blog as part of a series about companies that are Getting Great Science to Market. “I think there are certain cancers that this local delivery approach is highly relevant for,” says Ting. “This includes pancreas cancer, esophageal cancer and potentially mesothelioma—the ones we can’t get drugs into very well.”
Read More about Drug Delivery Directly to the Tumor – Innovation Blog | Mass General Brigham
Laura Indolfi Presents at MassBio 2019 Annual Meeting
Massachusetts is the epicenter of startup creation for biotech, but it’s not always easy to go from research to commercialization. Come hear founders and industry leaders on the panel “Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies” offer lessons learned on intelligently scaling your company amid rapid growth including when to partner, sell or IPO, or when to build or buy preclinical, manufacturing, and clinical development capabilities. PanTher CEO Laura Indolfi will be one of the panelists for this illuminating discussion hosted by the Massachusetts Biotechnology Council.
Read More about Laura Indolfi Presents at MassBio 2019 Annual Meeting
Amgen Awards PanTher with ‘Golden Ticket’ for LabCentral
Amgen and LabCentral announced that Kernal Biologics and PanTher Therapeutics each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a “Quick Pitch” event hosted by Amgen at its Cambridge, Mass., facility on Dec. 11, 2018. Six finalists pitched their business plans to attendees where the audience members’ votes served as input for the Amgen internal committee’s decision.
Read More about Amgen Awards PanTher with ‘Golden Ticket’ for LabCentral
Startup Spotlight: PanTher’s drug-delivery patch aims to knock down the ‘wall’ of pancreatic cancer
PanTher was featured on the STAT Startup Spotlight in December. Kate Sheridan provided an overview of the company technology and its status highlighting the interest of large pharma companies into the disruptive technology of our early-stage start-up. “Wherever there has been a stage for biotech entrepreneurs this fall, Laura Indolfi has appeared. And wherever she is, major pharmaceutical companies have been, too. Indolfi’s company, Cambridge, Mass.-based PanTher Therapeutics, has already received awards linked to Bristol-Myers Squibb and Johnson & Johnson. And on Tuesday, she competed for — and won — one of Amgen’s Golden Tickets — a one-year pass into LabCentral, the noted Cambridge lab-sharing space where PanTher is already headquartered.”
